Clinical Trials Sponsored by Southwest Oncology Group

Total 2214 results

Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia

Leukemia

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy

Pain | Breast Cancer | Musculoskeletal Complications

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy

Prostate Cancer | Metastatic Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7 | BRIP1 Gene Mutation | PALB2 Gene Mutation | ATM Gene Mutation | ATR Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | CHEK1 Gene Mutation | FANCA Gene... and other conditions

United States, Canada
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7 | FGFR1 Gene Amplification | FGFR2 Gene Amplification | FGFR2 Gene Mutation | FGFR3 Gene Mutation | FGFR1 Gene Mutation | FGFR3 Gene Amplification

United States, Canada
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma

United States, Canada
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma

Lung Cancer

United States
National Cancer Institute (NCI)
Southwest Oncology Group

Completed

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer

Recurrent Breast Carcinoma | HER2 Positive Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery

Malignant Mesothelioma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Terminated

S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis

Multiple Myeloma | Plasma Cell Myeloma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer

Colorectal Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer

Breast Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor

Sarcoma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma

Gallbladder Cancer | Extrahepatic Bile Duct Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo

Breast Cancer | Fatigue | Neurotoxicity | Neuropathy | Chemotherapeutic Agent Toxicity

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Terminated

S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma

Multiple Myeloma | Plasmacytoma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S8809-S9800-S9911TM- Biological Markers in Patients With Follicular Lymphoma Treated on Clinical Trial SWOG-8809, SWOG-9800, or SWOG-9911

Lymphoma
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

Multiple Myeloma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma

Multiple Myeloma | Plasma Cell Myeloma | Precancerous Condition

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9346A Blood Samples From Patients With Metastatic Prostate Cancer Previously Treated With Bicalutamide and Goserelin

Prostate Cancer
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0106A, Biomarkers in Samples From Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Cytarabine-Based Chemotherapy

Leukemia
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin

Bladder Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer (S0009)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9626: Megestrol in Treating Hot Flashes Following Treatment for Breast Cancer

Breast Cancer | Hot Flashes
Southwest Oncology Group
National Cancer Institute (NCI)

Terminated

S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer

Esophageal Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Pancreatic Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML

Leukemia

United States, Canada, Sweden
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Leukemia

United States, Canada
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9333A Study of Blood and Bone Marrow Samples From Patients With Previously Untreated Primary Acute Myeloid Leukemia

Leukemia
Southwest Oncology Group
National Cancer Institute (NCI)

Terminated

S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer

Gastric Cancer | Ovarian Cancer | Prostate Cancer | Brain Tumors

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Withdrawn

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma | Plasma Cell Myeloma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9031-S9333-S0112-S0301-A Biomarkers Associated With Response to Cytarabine in Samples From Older Patients With Acute Myeloid Leukemia

Leukemia
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0334 Analyzing Chromosomes in Patients With Newly Diagnosed Multiple Myeloma or Other Blood Disease

Lymphoma | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous/Nonmalignant Condition
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia

Lymphoma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9925: Collecting and Storing Samples From Patients With Lung Cancer

Lung Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma

Lymphoma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0430 Cyclophosphamide and Capecitabine in Treating Women With Stage IV Breast Cancer

Breast Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer

Prostate Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Arsenic Trioxide in Treating Men With Germ Cell Cancer

Testicular Germ Cell Tumor | Extragonadal Germ Cell Tumor

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

FR901228 in Treating Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Cancer

Colorectal Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Lung Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S8814A Biomarkers in Predicting Outcome in Postmenopausal Women With Hormone Receptor-Positive, Node-Positive Breast Cancer Treated With Tamoxifen With or Without Cyclophosphamide, Doxorubicin, and Fluorouracil

Breast Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Withdrawn

S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307

Breast Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Terminated

S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Lymphoma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0007 - Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

Head and Neck Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Withdrawn

S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer

Kidney Cancer
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9914: Combination Chemotherapy Plus Filgrastim in Untreated Extensive-Stage Small Cell Lung Cancer

Lung Cancer

United States

Clinical Trials Sponsored by Southwest Oncology Group

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations